Serum 25-Hydroxyvitamin D Levels in Breast Cancer Patients: A Cross-Sectional Analysis by Molecular Tumor Subtypes

Journal of Clinical Medicine 2026 Open access

Read full text
Authors: Dorota Weber, Andrzej Stanisławek, Anna Irzmańska–Hudziak, Teresa Bernadetta Kulik, Anna Beata Pacian, Monika Baryła‐Matejczuk, Marta Łuczyk, Robert Jan Łuczyk
DOI: 10.3390/jcm15020833
Cited by: 0
References: 26

Abstract

Background: Vitamin D deficiency has been implicated in breast cancer pathogenesis and prognosis. However, the relationship between serum 25-hydroxyvitamin D [25(OH)D] levels and molecular breast cancer subtypes remains incompletely understood. Methods: This cross-sectional study included 168 women (89 breast cancer patients, 79 healthy controls) from Poland. Serum 25(OH)D was measured by electrochemiluminescence immunoassay. Blood samples were collected year-round, with 54% obtained during winter/spring months (October–March). Molecular subtypes (luminal A, luminal B, HER2-enriched, triple-negative) were classified by immunohistochemistry. Results: Mean 25(OH)D was 30 ± 13 ng/mL, with 55% showing insufficiency (

Fields of Study & Subjects

Vitamin D Research Studies Breast Cancer Treatment Studies Cancer Risks and Factors

Publication details

Journal / source
Journal of Clinical Medicine
Volume
15
Issue
2
Pages
833–833
Publication date
20 January 2026
Language
EN